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Introduction: We designed OP3-4 (YCEIEFCYLIR), a cyclic peptide, to mimic the soluble osteoprotegerin (OPG), and
was proven to bind to RANKL (receptor activator of NF-κB ligand), thereby inhibiting osteoclastogenesis. We
recently found that another RANKL binding peptide, W9, could accelerate bone formation by affecting RANKL
signaling in osteoblasts. We herein demonstrate the effects of OP3-4 on bone formation and bone loss in a murine
model of rheumatoid arthritis.
Methods: Twenty-four seven-week-old male DBA/1J mice were used to generate a murine model of collagen-induced
arthritis (CIA). Then, vehicle or OP3-4 (9 mg/kg/day or 18 mg/kg/day) was subcutaneously infused using infusion
pumps for three weeks beginning seven days after the second immunization. The arthritis score was assessed, and the
mice were sacrificed on day 49. Thereafter, radiographic, histological and biochemical analyses were performed.
Results: The OP3-4 treatment did not significantly inhibit the CIA-induced arthritis, but limited bone loss. Micro-CT
images and quantitative measurements of the bone mineral density revealed that 18 mg/kg/day OP3-4 prevented the
CIA-induced bone loss at both articular and periarticular sites of tibiae. As expected, OP3-4 significantly reduced the
CIA-induced serum CTX levels, a marker of bone resorption. Interestingly, the bone histomorphometric analyses using
undecalcified sections showed that OP3-4 prevented the CIA-induced reduction of bone formation-related parameters
at the periarticular sites.
Conclusion: The peptide that mimicked OPG prevented inflammatory bone loss by inhibiting bone resorption and
stimulating bone formation. It could therefore be a useful template for the development of small molecule drugs for
inflammatory bone loss.Introduction
Many patients with rheumatoid arthritis (RA) still ex-
perience progressive bone erosion after primary treat-
ment using disease-modifying antirheumatic drugs
(DMARDs) [1]. Although the bone erosion of RA pa-
tients can be inhibited by tumor necrosis factor alpha
(TNFα) neutralizing therapies [2], the direct inhibition* Correspondence: kazu.hpha@tmd.ac.jp
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to newly formed bone is increased by bone resorption
inhibitors, the bone tends to accumulate microcracks,s distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Kato et al. Arthritis Research & Therapy  (2015) 17:251 Page 2 of 14leading to a reduction of the bone quality, followed by
atypical fractures [9–11]. In this context, a clinical trial
using parathyroid hormone (PTH), a stimulator of bone
formation and a bone resorption inhibitor [12], has been
initiated to determine whether such treatment can re-
duce the fracture risk. Since RA is accompanied by a
pathological state, which promotes bone resorption and
reduces bone formation, an anabolic drug with anti-
catabolic effects on bone is expected to be helpful to re-
duce the fracture risk.
OP3-4 (YCEIEFCYLIR) is a peptide that mimics oste-
oprotegerin (OPG). There are three binding sites for
RANKL on OPG, and OP3-4 was designed based on
the structure of the loop in the third cysteine-rich do-
main of OPG (OP3 site), one of the binding sites on
OPG [13]. OP3-4 binds to RANKL with high affinity,
thereby inhibiting osteoclastogenesis and bone resorp-
tion [13, 14]. Recently, the WP9QY peptide (W9), a
different RANKL binding peptide derived based on the
structures of tumor necrosis factor type 1 receptor/
receptor activator of nuclear factor-κB (RANK) recep-
tors [15, 16], was demonstrated to promote bone for-
mation, as well as to inhibit bone resorption [17]. Since
the ability of W9 to promote bone formation was de-
creased in osteoblasts isolated from RANKL-deficient
mice calvariae or RANKL-downregulated osteoblasts
(by small interfering RNA (siRNA) against RANKL), it
was suggested that the stimulatory effects of RANKL
binding peptides on bone formation might occur at
least partially via a RANKL-dependent mechanism
[17, 18]. We therefore hypothesized that the RANKL-
binding peptide OP3-4 would also stimulate bone for-
mation, as well as inhibit bone resorption.
In this study we performed osteoblast cultures to
evaluate the direct effects of OP3-4 on osteoblast differ-
entiation, and investigated the in-vivo effects of OP3-4
on bone resorption and bone formation using a murine
model of collagen-induced arthritis (CIA). We herein
demonstrate that OP3-4 promoted osteoblast differenti-
ation and nodule formation in vitro. The peptide also
prevented the increase in a serum bone resorption
marker induced by CIA, and decreased the osteoclast
number at the inflammatory sites. OP3-4 also prevented
the CIA-induced bone loss at the periarticular sites of
joints, promoting bone formation.
Materials and methods
Cell culture
Murine osteoclast precursors from 7-week-old male
C57BL/6J mice were obtained from Nippon CLEA (Tokyo,
Japan) and osteoclast-like cells were induced using cyto-
kines, as described elsewhere [19]. In brief, murine bone
marrow cells were cultured (6 × 105 cells/well in a 48-well
plate) in alpha-minimal essential medium (α-MEM; Sigma-Aldrich, St. Louis, MO, USA) containing 10 % fetal bovine
serum (FBS; Invitrogen, Grand Island, NY, USA), and
100 U/ml penicillin, 100 μg/ml streptomycin (Sigma-
Aldrich), and 25 ng/ml macrophage colony-stimulating
factor (M-CSF; R&D Systems, Minneapolis, MN, USA)
and 50 ng/ml RANKL (Wako, Osaka, Japan) in the
presence or absence of either 0.05 % dimethyl sulfoxide
(DMSO; Sigma-Aldrich), a control peptide (50 μM/l),
or OP3-4 (1, 5, or 50 μM/l). The cells were incubated
for 4 days at 37 °C. The OP3-4 peptide and the control
peptide (FCYISEVEDQCY) were both purchased from
American Peptide Company (Sunnyvale, CA, USA) [14].
Tartrate-resistant acid phosphatase (TRAP) staining was
performed after fixation, and the number of TRAP-
positive multinucleated cells (n >2) was counted.
An in-vitro osteoblastogenesis assay was carried out as
described previously [19]. Briefly, primary osteoblast-like
cells isolated from 1 day-old mice calvariae were seeded
(5 × 104 cells/well in a 24-well plate) and cultured in α-
MEM (Sigma-Aldrich) with 10 % FBS (Hana-Nesco Bio,
Brisbane, Australia) and 100 U/ml penicillin, 100 μg/ml
streptomycin (Sigma-Aldrich) containing 50 mg/ml as-
corbic acid (Wako), 10 mM β-glycerophosphate (Sigma-
Aldrich), and 10 nM dexamethasone (Sigma-Aldrich).
Alkaline phosphatase (ALP) staining was performed on
day 7 and von Kossa staining was performed on day 21
of culture, and the ALP-positive and von Kossa-positive
areas were measured using an image analysis system
(KS400; CarlZeiss, Jena, Germany), as described previ-
ously [19].
mRNA analyses
Primary osteoblast-like cells were cultured in the osteo-
genic medium as already described for the indicated days.
Total RNA was isolated from culture in osteogenic
medium using Trizol (Invitrogen) and was treated with
DNase I (Invitrogen). cDNA was synthesized using Prime-
Script II reverse transcriptase (Takara, Kyoto, Japan) ac-
cording to the manufacturer’s instructions. Quantitative
RT-PCR analysis was performed using SYBR Premix Ex
Taq II (Takara) and a LightCycler 2.0 (Roche, Basel,
Switzerland). For normalization, the expression of hypo-
xanthine guanine phosphoribosyl transferase (Hprt) was
measured as an endogenous reference gene. The following
primers specific for mouse were used: Hprt, sense 5′-CTT
TGC TGA CCT GCT GGA TT-3′ and antisense 5′-TAT
GTC CCC CGT TGA CTG AT-3′; Runx2, sense 5′-ACT
GGC GGT GCA ACA AGA C-3′ and antisense 5′-CGG
TAA CCA CAG TCC CAT CT-3′; Alp, sense 5′-GCA
CCT GCC TTA CCA ACT CT-3′ and antisense 5′-
TCA GGG CAT TTT TCA AGG TC-3′; and Bglap1/2
(ostocalcin), sense 5′-TAG TGA ACA GAC TCC GGC
GCT ACC TT-3′ and antisense 5′-AGC TCG TCA CAA
GCA GGG TTA AGC TC-3′. The relative levels of
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by the ΔΔCt method.
Induction of CIA
The induction and assessment of CIA were performed as
described previously [20]. Briefly, male DBA/1J mice
(7 weeks old, six mice per group; Charles River Laborator-
ies Japan, Kanagawa, Japan) were injected intradermally at
the base of the tail with 200 μg bovine type II collagen
(Collagen Research Center, Tokyo, Japan) in 0.05 M acetic
acid (Sigma-Aldrich) emulsified in complete Freund adju-
vant (CFA; Difco, Detroit, MI, USA). Twenty-one days
after the primary immunization, the mice were boosted in
the same way. The day of the first immunization was des-
ignated day 0. The mice were provided food (MF; Oriental
Yeast Company, Tokyo, Japan) and distilled water ad libi-
tum, and were maintained under a 12-hour light/dark
cycle. The experimental procedures were reviewed and
approved by the Animal Care and Use Committee of
Tokyo Medical and Dental University (Tokyo, Japan)
(authorization number: 120217A, 130255A, and 14070A).
Treatment with the OP3-4 peptide
The OP3-4 peptide was dissolved in phosphate-buffered
saline (PBS)-buffered 20 % DMSO (Sigma-Aldrich).
Alzet osmotic minipumps (Model 2001 or 2002; Alza,
Palo Alto, CA, USA) were prepared according to the
manufacturer’s instructions. On day 28, the mice were
anesthetized with injections of medetomidine hydro-
chloride (0.5 mg/kg; Meijiseika, Tokyo, Japan) and keta-
mine hydrochloride (50 mg/kg; Sankyo, Tokyo, Japan). A
1 cm incision was made in the skin, and the osmotic
minipumps filled with 20 % DMSO (vehicle) or OP3-4
peptide (to deliver 9 mg/kg/day or 18 mg/kg/day) were
subcutaneously implanted. The osmotic minipumps
were replaced on day 35 and day 42, and infusions were
continued until the mice were killed (on day 49). For
measurement of the bone formation parameters, calcein
(Sigma-Aldrich) was injected on days 42 and 47. The
mice (six per group) were divided into four groups:
nonimmunized mice receiving vehicle (20 % DMSO)
(Normal-vehicle group); immunized mice receiving ve-
hicle (20 % DMSO) (CIA-vehicle group); immunized
mice receiving 9 mg/kg/day OP3-4 peptide (CIA-9 mg
OP3-4 group); and immunized mice receiving 18 mg/kg/
day OP3-4 peptide (CIA-18 mg OP3-4 group).
Clinical assessment
To determine the arthritis score, two independent ob-
servers examined the mice daily from the day of the
second immunization. The day of arthritis onset was
considered to be when erythema and/or swelling was
first observed. The severity of arthritis was graded on a
0–4 scale [21]. Briefly, the criteria for the grading were asfollows: 0 = no evidence of erythema or swelling, 1 =
erythema and mild swelling confined to the tarsals or
ankle joint, 2 = erythema and mild swelling extending
from the ankle to the tarsals, 3 = erythema and moder-
ate swelling extending from the ankle to metatarsal
joints, and 4 = erythema and severe swelling encom-
passing the ankle, foot, and digits, or ankylosis of the
limb. Each paw was graded, and the four scores were
added together so that the maximum possible score
was 16 per mouse.
Radiographic assessment of arthritis
At the end of the experiment (day 49), the mice were killed
using domitor anesthesia, blood was collected from the or-
bital vein, and the hind paws were removed and fixed in
phosphate-buffered glutaraldehyde (0.5 %)–formalin (4 %)
fixative (pH 7.4) for 2 days, washed with PBS for 1 day and
then used for the radiographic analyses. Three-dimensional
reconstruction images and sagittal images of the knee
joints were obtained by microfocal computed tomography
(μCT) (Scan Xmate-E090; Comscan, Kanagawa, Japan)
[22]. Microarchitectural changes were then measured using
a three-dimensional bone structure analyzing system (TRI/
3D-BON; RATOC System Engineering, Tokyo, Japan) [23].
To exclude the primary spongiosa, the region of interest
(ROI) for the microstructural analyses of secondary spongi-
osa was set at 0.2–1.7 mm longitudinal length from the
proximal end of epiphysis, and trabecular bones where
bone separation was less than 60 μm (4 voxels) were ex-
cluded from the measurement [24]. For the analyses of
epiphysis, the two-dimensional ROI (150 μm width) along
the proximal end surface of tibiae was used. The BMD of
the knee joints was measured by dual X-ray absorptiometry
(DXA) (DCS-600R; Aloka, Tokyo, Japan) using the high-
resolution scanning mode. The ROI (2.0 × 2.0 mm) for
measuring the BMD at knee joints was determined by ex-
cluding the secondary spongiosa of the tibial and femoral
metaphysis.
Biochemical markers
The matrix metalloproteinase (MMP)-3, C-telopeptide
fragments of type I collagen (CTX), and osteocalcin
levels in the blood serum were analyzed according to the
manufacturers’ instructions: for MMP-3, Mouse ELISA
Kit (MMP 300) from R&D Systems, Inc. (Minneapolis,
MN, USA); for CTX, RatLaps ELISA Kit (DS-AC 06F1)
from Immunodiagnostic Systems Ltd (Fountain Hills,
AZ, USA); and for osteocalcin, Mouse Gla-Osteocalcin
High Sensitive EIA kit (MK 127) from Takara-Bio Inc.
(Otsu-city, Shiga, Japan).
Histological assessment of arthritis
The tibial bones were embedded in methyl methacrylate
monomer (MMA), as described elsewhere [25]. In brief,
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calcified sections (3 μm) were prepared using a fully au-
tomated rotary microtome Leica RM2265 device (Leica
Biosystems, Nussloch GmbH, Germany). The direction of
the cuts made in the bones was guided by μCT images of
embedded samples before the sections were made. After
removing MMA resin using 1-acetoxy-2-methoxyethane
(Wako), the sections were then stained with TRAP and
counterstained with toluidine blue. Histomorphometric
analyses [25] were performed using the KS400 system
(CarlZeiss). Some sections were stained according to the
von Kossa method to detect calcified tissue, and were
counterstained with modified van Gieson stain. Toluidine
blue-stained sections were used to detect the pannus infil-
tration site at the articular cartilage of the tibial epiphysis.
Histomorphometric evaluation of the epiphysis
The extent of cartilage degradation at the proximal end
of the tibia was calculated using undecalcified toluidine
blue-stained sections. The formula used was as follows:
Extent of cartilage degradation %ð Þ
¼ length of cartilage degradationð Þ =
total length of proximal end of tibial epiphysis;ð
excluding anterior intercondylar areaÞ  100:
The undecalcified sections that were stained with
TRAP and counterstained with toluidine blue were used
for the assessments. The calcified area/tissue area and
osteoclast number/bone volume (N.Oc/BV) ratios in the
epiphysis of the proximal tibia were measured using the
KS400 image analyzing system, as described previously
[20]. TRAP-positive multinucleated (n >2) cells that
formed resorption lacunae on the surface of the trabeculae
were designated osteoclasts. The labeled surface was also
measured in the region of epiphyses.
Bone histomorphometry of the tibial metaphysis
To investigate the secondary effects of CIA on bone re-
sorption, in addition to the resorption of periarticular
bone, standard histomorphometric analysis in the tibial
metaphysis was performed [20, 26] using the image ana-
lysis system already described.
The ROI for the histomorphometric analyses of the
metaphysis was set at 0.6 mm distal from the center of
the growth plate and the size of the ROI was 1.1 mm
(longitudinal length) × 0.7 mm (width) at the center of
diaphysis to exclude the primary spongiosa.
Statistical analysis
The Kruskal–Wallis test was performed to analyze the
arthritis score. For comparison purposes of each group,
the Mann–Whitney U test with Bonferroni correction
was applied. The other data were analyzed by ananalysis of variance. When an F test yielded significant
results (p <0.05), the groups were compared using
Fisher’s protected least significant difference post-hoc
test. Tests were carried out using an Apple software
program, StatView 4.1 (SAS Institute, Cary, NC, USA).
Values of p <0.05 were considered significant.
Results
The effects of OP3-4 on osteoclastogenesis and osteoblast
differentiation in vitro
Because OP3-4, an OPG mimetic peptide, is known to
inhibit osteoclastogenesis [13, 14], we first tried to con-
firm its effects on osteoclast formation in vitro. Bone
marrow cells from tibiae and femurs were cultured in
the presence of soluble RANKL and M-CSF for 4 days,
and the TRAP-positive multinucleated cells were counted.
As shown in Fig. 1a, b, OP3-4 inhibited the formation of
TRAP-positive multinucleated cells in a concentration-
dependent manner. The 50 μM concentration of OP3-4
decreased the number of TRAP-positive cells by 76 %
(Fig. 1b). On the contrary, 50 μM control peptide had little
effect on osteoclast-like cell formation.
Next, primary osteoblast-like cells were isolated from
1-day-old mice calvariae, and were cultured in the pres-
ence or absence of OP3-4 for 7 or 21 days. As shown in
Fig. 1c, d, the number of ALP-positive cells on day 7 of
culture was found to be significantly increased in a
concentration-dependent manner by OP3-4. The bone
nodule formation was determined by von Kossa staining
on day 21. As shown in Fig. 1e, f, the von Kossa-positive
area was significantly increased in a concentration-
dependent manner by OP3-4. In parallel with the results,
OP3-4 markedly enhanced mRNA expression of Runx2,
Alp, and Bglap1/2 (genes of osteocalcin), as shown in
Fig. 1g–i, suggesting that OP3-4 enhances osteoblast
differentiation as well as inhibiting osteoclastogenesis
in vitro.
OP3-4 treatment did not reduce the inflammatory indices
To clarify the effects of OP3-4 peptide on inflammatory
bone destruction, we evaluated its in-vivo effects in a
murine model of CIA (Fig. 2a). First, we assessed the de-
velopment of inflammation by scoring the clinical disease
activity daily from day 21 after the first immunization, as
described in Materials and methods. The disease activity
in vehicle-treated mice with CIA first appeared on day 25,
which was 4 days after the second immunization (Fig. 2b).
Vehicle or OP3-4 administrations were started after the
onset of the disease (day 28). The grade of arthritis was
not reduced significantly by the OP3-4 treatments during
the experimental period, although treatment with the
higher dose of OP3-4 tended to reduce the arthritis score
(Fig. 2b). When we measured the serum levels of MMP-3,
an inflammatory marker, at the end of the experiment, the
Fig. 1 Direct effects of OP3-4 on osteoclastogenesis and osteoblast differentiation. a Microscopic view of osteoclast formation in vitro. TRAP-positive
cells are shown (red). Bone marrow macrophages were treated with 25 ng/ml M-CSF and 50 ng/ml RANKL for 4 days. Scale bar represents 100 μm.
b Number of TRAP-positive multinucleated cells. Data presented as mean ± standard deviation (SD). *p <0.05, **p <0.01 vs. vehicle control, $p <0.05 vs.
1 μM OP3-4, ##p <0.01 vs. 5 μM OP3-4. c ALP-positive cells in the cultures of primary osteoblastic cells on day 7. d Percentage of ALP-stained areas in
each well. Data presented as mean ± SD. *p <0.05, **p <0.01 vs. vehicle control. e von Kossa-positive cells in the cultures of primary osteoblastic cells
on day 21. f Percentage of von Kossa-stained areas in each well. Data presented as mean ± SD. *p <0.05, **p <0.01 vs. vehicle control; ##p <0.01 vs. 50
μM OP3-4. All cultures were performed at least three times independently, and similar data were obtained each time. Representative images of cultures
and quantitative data are provided (n = 3–4/group in each independent experiment). g–i Gene expression analyses of Runx2 g, Alp h, and Bglap1/2
i by quantitative PCR were performed using the cells on day 5 (white bar) and day 14 (black bar). BMP bone morphogenetic protein
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no significant differences were detected among the experi-
mental groups (Fig. 2c). In addition, the changes in spleen
weight were comparable with those of the serum MMP-3
levels (Fig. 2d).
When we administered vehicle or OP3-4 from the same
day as the first immunization, OP3-4 did not affect signifi-
cantly the grade of arthritis, such as reduction of body
weight, arthritis score, and swelling of paws (Fig. S1A–C
in Additional file 1). Histological observation around the
hind limb heels (calcaneus) revealed infiltration of themononuclear cells into the joints in both vehicle-treated
and OP3-4-treated mice (Fig. S1E in Additional file 1). We
did not detect a significant difference in the inflammatory
score between the two groups (Fig. S1F in Additional
file 1). We also scored the number of proliferating cells
in the periarticular regions of calcaneus, which were posi-
tive for Ki-67 antigen by immunohistochemical staining,
but we did not detect a difference between vehicle-treated
and OP3-4-treated mice (Fig. S1G in Additional file 1).
These observations suggest that OP3-4 had a limited
effect on CIA progression and inflammatory responders.
Fig. 2 The in-vivo experimental protocol, the clinical score, and the inflammatory indices. a Collagen-induced arthritis (CIA) was induced by
primary (day 0) and secondary (day 21) immunizations with bovine type II collagen in CFA. Infusion pumps were implanted subcutaneously in
mice with CIA on day 28. b Arthritis scores (clinical severity of arthritis). The maximum possible score is 16, as described in Materials and
methods. Shown are the results of vehicle-treated mice with CIA (closed squares), mice with CIA treated with 9 mg/kg/day OP3-4 peptide
(closed triangles), mice with CIA treated with 18 mg/kg/day OP3-4 peptide (closed circles), and vehicle-treated nonimmunized mice (open
diamond). Values are mean ± SD (n = 6 mice per group). c Serum matrix metalloproteinase (MMP)-3 levels on day 49. d The spleen weight
was measured on day 49. Normal-vehicle group, nonimmunized mice receiving vehicle (20 % DMSO); CIA-vehicle group, immunized mice
receiving vehicle (20 % DMSO); CIA-9 mg OP3-4 group, immunized mice receiving 9 mg/kg/day OP3-4 peptide; CIA-18 mg OP3-4 group,
immunized mice receiving 18 mg/kg/day OP3-4 peptide
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by the μCT and DXA analyses
When we observed the three-dimensional μCT recon-
struction images of femurs, tibiae, knee joints, and ankle
joints, the CIA-vehicle group showed a reduction of the
radio-opaque area and bone erosion surface compared
with the Normal-vehicle group (Fig. 3a), confirming the
validity of the model. The OP3-4 treatment groups ex-
hibited recovery from the CIA-induced reduction of the
radio-opaque area and bone erosion surface (Fig. 3a, b).
To confirm the μCT observations, quantitative DXA
analyses were performed. Figure 3b shows the ROIs at the
knee joints for the DXA analyses. OP3-4 treatment signifi-
cantly inhibited the CIA-induced reduction of the BMD
and the bone mineral content, in a dose-dependent man-
ner (Fig. 3c, d). The reduction of BMD was also inhibitedwhen OP3-4 was administered from the first immunization
time point (Fig. S1D in Additional file 1). We also per-
formed two-dimensional analyses of the bone area close to
the knee joint space, shown in Fig. 3e, h. The significant re-
duction of bone area and average bone thickness were ob-
served in the vehicle-administered CIA group compared
with the Normal-vehicle group, but the 18 mg/kg/day
OP3-4 administration prevented the reduction significantly
(Fig. 3e–j).
OP3-4 prevented the articular cartilage destruction and
subchondral bone destruction at the epiphysis in the CIA
model
Histological observations of the toluidine blue-stained sec-
tions are shown in Fig. 4a. The area of metachromasia in-
dicated by toluidine blue staining at the articular site of
Fig. 3 (See legend on next page.)
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Fig. 3 Radiographic observations of femurs, tibiae, knee joints, and ankle joints. a μCT was used to clarify the structural changes of bones. Arrowheads,
erosion surface or site of the destruction of bones. OP3-4 appeared to inhibit the bone loss induced by collagen-induced arthritis (CIA). Scale bar
represents 1 mm. b ROIs used for the quantitative measurements of mineralized tissue at knee joints by DXA. The square areas (2 × 2 mm) are the ROIs
used for the DXA analyses. c BMD and d bone mineral content at the joint. The regions of interest shown in light gray for measuring the indices (f/g
and i/j) to show the changes of e femur epiphysis and h knee joint, respectively. Data presented as mean ± SD (n = 6). **p <0.01 vs. Normal-vehicle;
#p <0.05, ##p <0.01 vs. CIA-vehicle. Normal-vehicle group, nonimmunized mice receiving vehicle (20 % DMSO); CIA-vehicle group, immunized mice
receiving vehicle (20 % DMSO); CIA-9 mg OP3-4 group, immunized mice receiving 9 mg/kg/day OP3-4 peptide; CIA-18 mg OP3-4 group, immunized
mice receiving 18 mg/kg/day OP3-4 peptide
Kato et al. Arthritis Research & Therapy  (2015) 17:251 Page 8 of 14tibiae was reduced in the CIA-vehicle group compared
with the Normal-vehicle group. When compared with the
CIA-vehicle group, OP3-4 seemed to increase the area of
metachromasia at the articular site of tibiae. To clarify the
effects of OP3-4 on cartilage destruction, we measured
the articular surface of proximal tibiae, which had no area
of metachromasia following toluidine blue staining. To
clarify the cartilage degradation, we designated the cartil-
age degradation surfaces as “an extent of cartilageFig. 4 Histological observations and quantitative analyses of the articular s
blue-stained undecalcified sections. The area of metachromasia after toluid
length of the cartilage degradation site facing the proximal end of the tibi
panels, respectively. b The extent of cartilage degradation = (length of cart
epiphysis, excluding anterior intercondylar area) × 100. c von Kossa-stained
tibial epiphysis obtained by bone histomorphometry. Scale bar represents
epiphysis. f Serum levels of C-terminal telopeptides of type I collagen (CTX-
as mean ± SD (n = 6). **p <0.01 vs. Normal-vehicle; #p <0.05, ##p <0.01 vs.
vehicle (20 % DMSO); CIA-vehicle group, immunized mice receiving vehicle
9 mg/kg/day OP3-4 peptide; CIA-18 mg OP3-4 group, immunized mice recdegradation”. When the length ratio of the “cartilage
degradation surface” to the total length of the proximal
end of the tibial epiphysis was calculated, the CIA-vehicle
group showed a significantly increased value compared
with the Normal-vehicle group, in which the “cartilage
degradation surface” was not detectable (Fig. 4b). This
histomorphometric assessment revealed that OP3-4
treatment significantly inhibited CIA-induced cartilage
degradation in a dose-dependent manner (Fig. 4b). Theites of tibiae. a Representative microscopic images of toluidine
ine blue staining was decreased in the CIA-vehicle group. Arrows,
ae. Scale bars represent 500 μm and 250 μm in the upper and lower
ilage degradation surface) / (total length of proximal end of tibial
sections at the tibial epiphysis. d Calcified area measurements at the
1 mm. e Osteoclast number per bone surface (N.Oc/BS) at the tibial
I) on day 49. g Serum levels of osteocalcin on day 49. Data presented
CIA-vehicle. Normal-vehicle group, nonimmunized mice receiving
(20 % DMSO); CIA-9 mg OP3-4 group, immunized mice receiving
eiving 18 mg/kg/day OP3-4 peptide. CIA collagen-induced arthritis
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age cell line by the OP3-4 treatment supported these ob-
servations in vivo (Additional file 2).
To assess the effects of OP3-4 on articular bone de-
struction and bone metabolism, a histomorphometric
analysis was also performed on the tibial epiphysis. OP3-
4 seemed to prevent the CIA-induced reduction of the
trabecular thickness (Fig. 4c). Quantitatively, the CIA-
vehicle group exhibited a significantly decreased calcified
area compared with the Normal-vehicle group. Both
OP3-4 treatment groups had greater calcified areas com-
pared with the CIA-vehicle group (Fig. 4d). The number
of osteoclasts per bone surface (N.Oc/BS) was signifi-
cantly increased in the CIA-vehicle mice compared with
Normal-vehicle mice. This higher ratio in N.Oc/BS was
significantly reduced in both OP3-4-treated groups
(Fig. 4e). These results indicate that OP3-4 peptide could
inhibit the CIA-induced bone loss and bone erosion at
the tibial epiphysis. To clarify the systemic bone resorp-
tion activity, serum CTX levels were measured and were
found to be significantly greater in the CIA-vehicle
group compared with the Normal-vehicle group. This
high level of serum CTX was also significantly reduced
in both OP3-4-treated groups (Fig. 4f ). The serum levels
of osteocalcin, a bone formation marker, were similar in
all four groups at the end of the experiments (day 49)
(Fig. 4g).
OP3-4 prevented periarticular bone loss at the tibial
metaphysis in CIA mice
Since it is well known that CIA causes periarticular
bone loss, as well as articular bone destruction, the
secondary spongiosa in the tibial metaphysis was also
analyzed using peripheral quantitative computed tom-
ography (pQCT) and μCT reconstruction images.
Figure 5b shows the ROIs for BMD measurements of
the tibial secondary spongiosa by pQCT, indicating
that the longitudinal positioning of the ROI setting
was correct, since the distance between the fibula and
tibia was almost the same among the different groups
(Fig. 5a, upper panel).
The trabecular BMD of the tibial metaphysis was re-
duced in the CIA mice compared with the Normal-
vehicle group (Fig. 5b). Treatment with the 18 mg/kg/
day OP3-4 infusion significantly inhibited the decrease
in the trabecular BMD induced by CIA (Fig. 5b).
The μCT images showed the micro-architectural
changes of the tibial metaphysis. The CIA-vehicle group
showed a reduction in the trabecular number (Tb.N;
Fig. 5d) and the degree of connectivity of trabeculae nor-
malized by tissue volume (Conn.D; Fig. 5i), and a high
level of the architectural indices structure model index
(SMI; Fig. 5e), trabecular bone pattern factor (TBPf;
Fig. 5f ), marrow space star volume (V m.space; Fig. 5g),and trabecular spacing (Tb.Spac; Fig. 5h), while OP3-4
treatments significantly prevented the decrease in Tb.N
and Conn.D induced by CIA and the increase in the
SMI, TBPf, V m.space, and Tb.Spac (Fig. 5d–i).
OP3-4 promoted the bone formation parameters in the
secondary spongiosa at the tibial metaphysis in CIA mice
To clarify the effects of OP3-4 on the bone formation in
the CIA model, calcein injections were performed 7 days
and 2 days before sacrifice. When we observed undecal-
cified thin sections under a fluorescent microscope, the
distance between the calcein double labels seemed to
be narrower in the CIA-vehicle group than in the
Normal-vehicle group, and OP3-4 seemed to prevent
the CIA-induced reduction of the distance (Fig. 6a–c).
To confirm these histological observations, a bone
histomorphometric study was performed. The mineral
apposition rate (MAR), which indicates the bone for-
mation ability of osteoblasts, was significant reduced in
the CIA-vehicle group compared with the Normal-
vehicle group, while OP3-4 treatment prevented the re-
duction of the MAR in a dose-dependent manner
(Fig. 6d). The mineralizing surface per bone surface
(MS/BS) was not significantly different among the four
groups (data not shown). Consequently, the bone for-
mation rate (BFR), which reflects the total amount of
bone formation in a day, showed similar changes to
those of the MAR since BFR is defined as follows; BFR =
MS/BS × MAR (Fig. 6e). The BFR in a total tissue refer-
ence, which shows the total amount of calcified tissue in a
year, also showed similar or even prominent changes com-
pared with the BFR in a bone surface reference (Fig. 6f).
The trabecular thickness and the osteoblast surface were
also measured (Fig. 6g, h). To clarify the site difference in
bone formation activity, we measured the labeling surface
at the tibial epiphysis, but no significant effects appeared
among groups (Fig. 6i).
Discussion
In this study we first demonstrated the concentration-
dependent acceleration of osteoblast differentiation and
nodule formation by OP3-4, an OPG mimetic, in vitro.
Secondly, in the murine CIA model, although OP3-4 did
not significantly ameliorate the CIA symptoms the peptide
did increase the MAR, and consequently the BFR, at the
tibial secondary spongiosa, which was clearly demonstrated
by a histomorphometric study using calcein double label-
ing. Since the MAR indicates the function of osteoblasts in
terms of the calcification, our data suggest that OP3-4 also
promoted bone formation in vivo. We also confirmed the
inhibitory effects of OP3-4 on osteoclastogenesis. These
changes in the bone at periarticular sites were similar to
those induced by OPG treatment, as reported previously
[27], but the mechanism by which the treatment prevents
Fig. 5 OP3-4 prevented CIA-induced peripheral bone loss at the tibial metaphysis. a, b pQCT was used to measure the bone mineral density
(BMD) at the secondary spongiosa of the tibiae. Upper panels, representative scan images from the pQCT analyses; lower panels, trabecular area for
each group; right panel, color table for the BMD. c μCT reconstruction images of the tibial metaphysis. Scale bar represents 200 μm. d Trabecular
number (Tb.N; measure of the average number of trabeculae per unit length). e Structure model index (SMI; an indicator of the structure of
trabeculae). SMI will be 0 for parallel plates and 3 for cylindrical rods. f Trabecular bone pattern factor (TBPf; an indicator of morphological changes
of trabecular surface). g Marrow space star volume (V m. space; an indicator of osteoporotic changes). h Trabecular spacing (Tb.Spac). i Degree of
connectivity of trabeculae normalized by tissue volume (Conn.D). Data expressed as mean ± SD (n = 6) for each group. **p <0.01 vs. Normal-vehicle;
#p <0.05, ##p <0.01 vs. CIA-vehicle. Normal-vehicle group, nonimmunized mice receiving vehicle (20 % DMSO); CIA-vehicle group, immunized mice
receiving vehicle (20 % DMSO); CIA-9 mg OP3-4 group, immunized mice receiving 9 mg/kg/day OP3-4 peptide; CIA-18 mg OP3-4 group, immunized
mice receiving 18 mg/kg/day OP3-4 peptide. CIA collagen-induced arthritis
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anabolic effect on bone. Taken together, our study suggests
that subcutaneous injections of OP3-4 prevented the peri-
articular bone loss at the secondary spongiosa of the tibialmetaphysis, inhibiting bone resorption and promoting
bone formation.
One of the stimulatory effects of OP3-4 on bone for-
mation is thought to be exerted via a reversal in the
Fig. 6 Fluorescent images of undecalcified sections of the periarticular sites in tibiae. a Representative fluorescent images of the proximal
tibiae. Scale bar represents 1 mm. b Representative fluorescent images of the secondary spongiosa of the tibiae. Scale bar represents 50 μm.
c Magnified images of calcein double labeling of the trabecular bone. d Mineral apposition rate (MAR)/day. e Bone formation rate (BFR)/day in
a bone surface reference. f BFR/year in a total tissue reference. g Trabecular thickness (Tb.Th). h Osteoblast surface per bone surface (Ob.S/BS).
i Labeling surface at epiphysis. Data expressed as mean ± SD (n = 6) for each group. *p <0.05, **p <0.01 vs. Normal-vehicle; #p <0.05,
##p <0.01 vs. CIA-vehicle. Normal-vehicle group, nonimmunized mice receiving vehicle (20 % DMSO); CIA-vehicle group, immunized mice
receiving vehicle (20 % DMSO); CIA-9 mg OP3-4 group, immunized mice receiving 9 mg/kg/day OP3-4 peptide; CIA-18 mg OP3-4 group,
immunized mice receiving 18 mg/kg/day OP3-4 peptide. CIA collagen-induced arthritis
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findings of our previous study, where we proposed that
another RANKL-binding peptide (W9) could promote
bone formation through membrane-bound RANKL inosteoblasts [17]. Although the equilibrium constant (Kd)
values of W9 and OP3-4 for RANKL are 3.76 × 10−7
[28] and 3.89 × 10−6 [13], respectively, the binding dis-
sociation constant (Koff ), an important parameter of the
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2.85 × 10−3; OP3-4, 9.37 × 10−4 [13]), suggesting that
both W9 and OP3-4 similarly bind to RANKL, making a
stable complex, then lead to the reversal signaling in os-
teoblasts. Since PTH can work as an anabolic peptide
only when osteoclasts are present, some factors derived
from osteoclasts are thought to be necessary for the ana-
bolic effects of PTH [29, 30]. In contrast, OP3-4 might
directly stimulate osteoblasts via a mechanism other
than that involving PTH.
The RANKL reverse-signaling phenomena have already
been clarified in an osteoblastic cell line with regard to
RANKL membrane trafficking [31]. Kariya et al. [31]
demonstrated that the interaction between RANK-Fc-
conjugated beads (RANK-coated beads) and membrane-
bound RANKL leads to an increase in membrane-bound
RANKL by promoting the trafficking of RANKL-
containing vesicles to the cell membrane. RANK-coated
beads also stimulate ALP activity [32]. RANK-Fc alone
does not stimulate ALP activity, but the oligomerization of
RANK-Fc by IgM or RANK-Fc conjugation on the surface
of beads can stimulate ALP activity [32]. The OP3-4 pep-
tide, which works as a small RANK [13], stimulated ALP
activity only at the higher concentration (200 μM). At
higher concentrations, the OP3-4 peptide seemed to be
precipitated in vitro, suggesting aggregation of the peptide
at higher concentration which might induce conform-
ational changes that resemble RANK oligomerization,
leading to RANKL clustering on the surface of osteoblasts.
The promotion of RANKL trafficking could help to induce
RANKL clustering on the cell membrane. The RANKL-
binding peptide could stimulate bone formation, but
neither OPG nor an anti-RANKL antibody could stimu-
late bone formation [33, 34]. This might be because OPG
and the anti-RANKL antibody cannot induce auto-
oligomerization [35]. The higher concentration of the
RANKL-binding peptide could stimulate the auto-
oligomerization and induce RANKL clustering, which
might switch on the RANKL-reverse signaling to stimulate
ALP activity. Similar inverse-agonistic activity by CD4 pep-
tide mimics in T-cell activation has been observed [36].
Further studies are necessary to clarify the detailed mecha-
nism(s) underlying the effects of OP3-4 on bone formation.
In this study, OP3-4 treatment seemed to reduce the
CIA-induced clinical score, although not significantly.
The high dose of OP3-4 may seem to reduce the clinical
score because of secondary effects resulting from the
prevention of CIA-induced bone loss. Because a score of 4
was defined as ankylosis of the limb, the strong inhibitory
effect of OP3-4 on bone loss may have prevented the de-
velopment of ankylosis of the limb, leading to a reduction
of the clinical score in the high-dose OP3-4-treated mice.
Conversely, OP3-4 may not prevent the induction of im-
mune response nor inflammatory response. Infiltration ofmononuclear cells into the joints and proliferation of cells
in periarticular region were not inhibited even in mice
administered OP3-4 immediately before the first immu-
nization. We did not see an increase in the serum MMP-3
level, an inflammatory marker, in the CIA group, suggest-
ing that the mice had already passed the peak of inflam-
mation at the time of sacrifice. In addition, the serum
osteocalcin level was not reflected in the data for the bone
formation parameters at the secondary spongiosa of the
tibia, as shown in Fig. 6, also suggesting that the mice in
the CIA group had passed the peak reduction in bone for-
mation by the time of sacrifice.
The discrepancy between the serum osteocalcin level
and bone formation parameters at the periarticular site
could be explained by the restricted changes at the sec-
ondary spongiosa. The region we measured as a peri-
articular site was composed of a small bone volume
compared with the whole skeletal bone, including the
cortical bone compartment. This could be the reason
why the bone histomorphometric changes of the bone
formation indices at the periarticular site did not reflect
the changes of the serum osteocalcin levels or the sys-
temic changes of bone formation.
In this study, OP3-4 prevented the CIA-induced cartil-
age destruction. Since the major cartilage destruction
and subchondral bone destruction are thought to be me-
diated by osteoclasts existing at the leading edge of the
pannus [37, 38], the inhibitory effects of OP3-4 on oste-
oclasts are thought to prevent the cartilage destruction,
as alendronate treatment was reported to prevent cartil-
age destruction in a rabbit model of osteoarthritis [39].
On the other hand, the injection of denosumab, an anti-
RANKL antibody, was reported to have a much smaller
effect on joint space narrowing and cartilage destruction
compared with TNFα neutralizing therapy, since it does
not affect joint inflammation [40]. These reports suggest
that the inhibition of cartilage destruction by OP3-4
might not be due merely to the inhibition of osteoclasts.
Furthermore, the effects of OPG on cartilage destruction
are varied, although there is consensus that OPG does
not affect inflammation [27, 41, 42]. In our preliminary
experiments, we found the OP3-4 could stimulate the
proliferation and differentiation of ATDC5 mouse embry-
onic chondrocyte cells (Fig. S2 in Additional file 2).
Further studies will also be necessary to clarify the mech-
anism by which OP3-4 inhibits cartilage destruction.
When comparing macromolecules, the peptide-type
drug candidate OP3-4 might have fewer side effects and
lower production costs than agents such as antibodies
[43]. However, with regard to clinical applications, a
sustained-release carrier for OP3-4 needs to be developed
since peptide drugs are unstable and aggregate easily
in vivo. The effects of OP3-4 in this study were achieved
using infusion pumps subcutaneously implanted into the
Kato et al. Arthritis Research & Therapy  (2015) 17:251 Page 13 of 14backs of the mice. As we have previously shown, a
cholesterol-bearing pullulan (CHP) can be used to make
nanogels, or gelatin hydrogels could be candidate peptide
carriers [44, 45]. In the case of the W9 peptide, the use of
CHP nanogels could reduce the injection frequency from
eight times a day to once or twice a day (subcutaneous in-
jections) while still maintaining the inhibitory effects of
W9 on bone resorption [45, 46]. For the systemic adminis-
tration of peptide drug, the development of carriers that
can prevent peptide aggregation and allow the peptide
drug to remain biologically functional is essential prior to
clinical use.
Conclusion
We have herein demonstrated that the RANKL-binding
peptide OP3-4 increased bone formation at periarticular
sites, and also decreased bone resorption, preventing
bone loss due to CIA. The peptide drug, which was de-
signed based on OPG, could be a lead drug candidate
for RA treatment, and both inhibits bone resorption and
stimulates bone formation, leading to less bone loss and
a higher quality of the bones.
Additional files
Additional file 1: Figure S1. Showing that OP3-4 administration has a
limited effect on the induction and inflammation of arthritis. A–C The
osmotic minipumps filled with 20 % DMSO (vehicle) or OP3-4 peptide
(to deliver 18 mg/kg/day) were implanted subcutaneously before the first
immunization. Body weight A, arthritis score B, and paw swelling by
caliper measurement C of mice with CIA treated with vehicle (closed
squares), mice with CIA treated with 18 mg/kg/day OP3-4 peptide (closed
circles), and normal mice treated with vehicle (open diamond) are indicated.
There is no significant difference between vehicle-treated and OP3-4-treated
mice. D BMD measured by DXA. **p <0.01 vs. Normal-vehicle, #p <0.05 vs.
CIA-vehicle. E Histological images of hematoxylin and eosin staining of hind
limb heels are shown. Lower panels, higher magnification of the squares in
the upper panels. Bars indicate 1 mm. F Inflammatory scores in each group
of mice show no significant difference between CIA-vehicle and CIA-OP3-4
mice. **p <0.01 vs. Normal-vehicle. G Numbers of proliferating cells which
are positive for Ki-67 antigen counted in the periarticular region. No
significant differences are detected. (JPEG 3012 kb)
Additional file 2: Figure S2. Showing the effects of OP3-4 on the
proliferation and differentiation of cartilage cell line ATDC5. A Results of
proliferation assay on day 1 with the noninduction medium. B Alcian
blue-positive area ratio in the cartilage induction medium on day 10.
**p <0.01 vs. vehicle control, #p <0.05 vs. 100 μM OP3-4. (JPEG 384 kb)
Additional file 3: Presents supplementary methods. (DOC 22 kb)
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